Johnson & Johnson invests $3.3 billion in eye drug OLN324
J&J will pay $2.2 billion upfront plus $1.1 billion in milestones to acquire Ollin Biosciences. Blackstone Life Sciences will contribute $750 million to support Phase 3 trials of OLN324.
- Field
- drugs and trials
- What they did
- Johnson & Johnson plans to acquire biotech startup Ollin Biosciences for $2.2 billion to gain access to the drug OLN324 for treating age-related macular degeneration and diabetic macular edema.
- Why it matters
- This acquisition will allow Johnson & Johnson to compete with blockbuster therapies like Roche's Vabysmo and will bring an additional $750 million from Blackstone Life Sciences to support Phase 3 testing.
#johnson & johnson#ollin biosciences#biotech acquisition#ophthalmology#drug development



